ACSL5 Inhibitor Compounds for Metabolic and Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aberrations in fatty acid trafficking and metabolism are associated with obesity, non-alcoholic fatty liver disease (NAFLD), and type 2 diabetes, and ACSL5 dysregulation plays a role in metabolic and oncologic diseases.
Innovation Solution
Development of compounds that inhibit ACSL5, which are used to treat metabolic disorders such as metabolic dysfunction-associated steatohepatitis (MASH), non-alcoholic fatty liver disease (NAFLD), obesity, and type 2 diabetes, as well as cancers like acute myeloid leukemia (AML) and breast cancer, by modulating ACSL5 function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ACSL5 is inhibited to treat metabolic disorders, then insulin sensitivity improves and adiposity reduces, but potential harmful effects on fatty acid metabolism may occur
Solution Approach 1:
The patent modifies the chemical structure of ACSL5 inhibitors by changing parameters such as introducing specific functional groups (carboxylic acid, ester, amide) at defined positions in the molecule. This allows optimization of binding affinity to ACSL5 while controlling metabolic effects, resolving the contradiction between improving insulin sensitivity and avoiding harmful fatty acid metabolism disruption.
Solution Approach 2:
The patent applies local quality by placing specific functional groups at specific positions within the molecular structure. For example, positioning a carboxylic acid group at a particular location provides different binding characteristics compared to the same group at another position, allowing selective modulation of ACSL5 activity to achieve therapeutic effects with minimal harmful side effects.
2Reliability
If ACSL5 is inhibited to treat cancer, then cancer cell growth is suppressed, but normal cellular fatty acid metabolism may be affected
Solution Approach 1:
The patent optimizes inhibitor parameters including molecular weight, functional group composition, and spatial arrangement to achieve selective binding to ACSL5 in cancer cells. This specificity allows suppression of cancer cell growth while minimizing disruption to normal cellular fatty acid metabolism, resolving the contradiction between cancer treatment efficacy and preservation of normal metabolism.
Solution Approach 2:
The patent uses local quality by creating molecular structures with specific functional groups positioned to interact preferentially with ACSL5 in cancer cells. This localized interaction approach enables cancer-selective inhibition while sparing normal cells with different metabolic profiles, thus improving cancer treatment efficacy without harmful effects on normal cell metabolism.
3Reliability
If ACSL5 inhibitors are developed as pharmaceutical compounds, then therapeutic effectiveness is achieved, but compound complexity and synthesis difficulty increase
Solution Approach 1:
The patent segments the molecular structure into distinct functional modules: a core scaffold and detachable functional groups (carboxylic acid, ester, amide). This segmentation allows independent optimization of each module for therapeutic effectiveness while maintaining manageable synthesis complexity, as each segment can be introduced through standardized chemical transformations.
Solution Approach 2:
The patent systematically varies parameters such as the type of functional group, its position in the molecule, and its substituents to optimize therapeutic effectiveness. By changing these parameters in a structured manner, the patent achieves potent ACSL5 inhibition while keeping synthesis procedures manageable through established chemical methodologies.
Data Source
AI summary
Compounds useful as ACSL5 inhibitors, methods of their preparation and use, and pharmaceutical compositions comprising them are disclosed. Particular compounds are of the formula: